PCR-free detection of microRNA-122 from serum – A platform comparison study between Luminex MAGPIX and FLEXMAP 3D

Dajana Kolanovic (Vortragende:r), Valerie Regele (Vortragende:r), Antonio Marin Romero, Manuela Hofner, Juan Jose Diaz-Mochon, Christa Nöhammer, Salvatore Pernagallo

Publikation: Posterpräsentation ohne Beitrag in TagungsbandPosterpräsentation ohne Eintrag in Tagungsband


Background: MicroRNAs (miRNAs) are a crucial group of small, non-coding RNAs that regulate gene
expression and participate in almost all biological processes, such as cell proliferation, differentiation,
and apoptosis. Besides being important cellular regulators miRNAs have become useful biomarkers in
diagnosis of numerous diseases [1]. The altered expression of individual miRNAs has been
demonstrated in numerous cancers [1]. However, detecting and quantifying miRNAs accurately can be
challenging, often relying on PCR amplification, which doesn’t allow direct analysis. Here, we are
introducing a novel method for direct and PCR-free detection of microRNA-122 (miR-122) [2], a
promising biomarker for liver function and liver disease diagnosis.
Methods: The current study describes a comparative performance assessment between Luminex
MAGPIX® and FLEXMAP 3D® platforms to detect miR-122 in human serum. Experiments were
performed under comparable conditions using DESTINA’s ChemiRNATM technology on the two Luminex
platforms. Assay procedure: a) Modified capture probes (complementary to target miR-122) are
conjugated onto Luminex microspheres; b) Microspheres are incubated with serum sample; c)
Modified capture probes hybridize with miR-122, forming a chemical pocket; d) A modified base binds
in the pocket which can be detected after the application of streptavidin-phycoerythrin. This
comparative study has included six serum samples of liver-diseased individuals, as well as four control
samples of symptom-free individuals, measured in triplicates and quantified using a 9-point standard
Results: We observed FLEXMAP to be more sensitive in detecting miRNA-122 and resulting in higher
signal intensities than MAGPIX. This result was not unexpected as MAGPIX measures fluorescence with
CCD cameras after LED illumination of a single layer of microspheres, whereas FLEXMAP uses a flow
cytometer-based technology in combination with lasers.
Conclusions: ChemiRNA™ Technology applied to Luminex microspheres enables direct quantification
of miR-122 and can be used in combination with both platforms (MAGPIX and FLEXMAP) depending
on given sensitivity requirements.
[1] Condrat et al. miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis
and Prognosis Cells. 2020, 9(2): 276.
[2] Marín-Romero et al. Amplification-free profiling of microRNA-122 biomarker in DILI patient
serums, using the luminex MAGPIX system. Talanta. 2020, 219:121265.
PublikationsstatusVeröffentlicht - 2023
VeranstaltungCCC-Trio 2023 Symposium: Cutting-Edge Krebstherapie und -Forschung - Vienna, Österreich
Dauer: 27 Apr. 202328 Apr. 2023


KonferenzCCC-Trio 2023 Symposium

Research Field

  • Molecular Diagnostics


Untersuchen Sie die Forschungsthemen von „PCR-free detection of microRNA-122 from serum – A platform comparison study between Luminex MAGPIX and FLEXMAP 3D“. Zusammen bilden sie einen einzigartigen Fingerprint.

Diese Publikation zitieren